drugset

drugset / Trial / NCT05562349

Clavulanic Acid for the Treatment of Cocaine Use Disorder

NCT05562349 ↗

Phase 2 Active not recruiting 65 enrolled Temple University Medical University of South Carolina · collab Research Foundation for Mental Hygiene, Inc. · collab University of Pennsylvania · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A dose escalation study to assess the efficacy and safety of Clavulanic Acid (CLAV) vs. placebo (PBO) for the treatment of cocaine use disorder (CUD)

Timeline

Start: 2023-05-03
Primary completion: 2024-07
Completion: 2024-07

Publications

Results Kim J, John J, Langford D, Walker E, Ward S, Rawls SM. Clavulanic acid enhances glutamate transporter subtype I (GLT-1) expression and decreases reinforcing efficacy of cocaine in mice. Amino Acids. 2016 Mar;48(3):689-696. doi: 10.1007/s00726-015-2117-8. Epub 2015 Nov 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	clavulanic acid	Small molecule	500 mg	—
Subject	clavulanic acid	Small molecule	750 mg	—

Indications